GIS is making a direct impact on health through its efforts to understand disease particularly prevalent in Asia. Our research in this area allows us to interface with the local clinician community and together reach out to industries. We have several large scale projects that position us to make "bench to bedside" tangible. The following programmemes aim to lead to implementation of genomics technologies in the clinic.
The POLARIS programme uses next generation genomic technology in the management of disease therapy. It leverages upon the technical and research expertise developed in GIS, in order to match the right drug to the right patient at the right time.
The Molecular Diagnostics Group focuses on technology development and validation to facilitate adoption of GIS’ research discoveries in the clinic. Through active collaborations with clinicians and industry, we develop assays that integrate the excellent foundation of biomarker, diagnostics and algorithm research at. GIS
SAPhIRE is a strategic partnership to improve drug safety by developing genomic biomarkers that are predictive of specific adverse drug reactions (ADRs).